688 related articles for article (PubMed ID: 24398308)
1. [First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute].
Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):8-14. PubMed ID: 24398308
[TBL] [Abstract][Full Text] [Related]
2. [Second-line chemotherapy and its survival analysis of 181 patients with extensive-stage small cell lung cancer in a single institute].
Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
Zhongguo Fei Ai Za Zhi; 2013 Nov; 16(11):572-8. PubMed ID: 24229622
[TBL] [Abstract][Full Text] [Related]
3. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
[TBL] [Abstract][Full Text] [Related]
4. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract][Full Text] [Related]
5. Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial.
Yu TT; Hu X; Liufu WJ; Niu SQ; Lian HM; Ma HL; Wang J; Bao Y; Chen M; Peng F
Cancer Med; 2024 Apr; 13(8):e7215. PubMed ID: 38659392
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy.
Qi W; Zhao S; Chen J
Cancer Biomark; 2021; 31(2):177-185. PubMed ID: 33896825
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period.
Ni J; Zhang X; Wang H; Si X; Xu Y; Zhao J; Chen M; Zhang L; Wang M
Thorac Cancer; 2022 Feb; 13(4):539-548. PubMed ID: 34970848
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations.
Han J; Fu C; Li B
Radiat Oncol; 2021 Mar; 16(1):47. PubMed ID: 33663551
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
Jiang S; Huang L; Zhen H; Jin P; Wang J; Hu Z
BMC Cancer; 2021 Dec; 21(1):1308. PubMed ID: 34876060
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
[TBL] [Abstract][Full Text] [Related]
13. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of Prognostic Factors and Clinical Characteristics for Patients with Limited Stage Small Cell Lung Cancer with Pleural Effusion].
Xu K; Wang Y; Qi J; Zhao L; Wang P
Zhongguo Fei Ai Za Zhi; 2018 Jan; 21(1):16-23. PubMed ID: 29357968
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as
Second-line Treatment for Small Cell Lung Cancer].
Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
[TBL] [Abstract][Full Text] [Related]
16. [Retrospectively Analysis of Factors Influencing the Relapse (or Progression) of Newly Diagnosed Nonoperative Small Cell Lung Cancer].
Zhuang Y; Jiang L; Zhao Y; Qian J; Gao X
Zhongguo Fei Ai Za Zhi; 2015 Sep; 18(9):529-36. PubMed ID: 26383975
[TBL] [Abstract][Full Text] [Related]
17. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factor analysis of patients with small cell lung cancer: Real-world data from 988 patients.
Ma X; Zhang Z; Chen X; Zhang J; Nie J; Da L; Hu W; Tian G; Wu D; Han J; Han S; Long J; Wang Y; Fang J
Thorac Cancer; 2021 Jun; 12(12):1841-1850. PubMed ID: 33955685
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer.
Luo H; Zhang L; Yang B; Feng Y; Xiong Y; Zhang S; Li X; Qian C; Dong W; Dai N
Invest New Drugs; 2020 Feb; 38(1):148-159. PubMed ID: 31399906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
